0001225208-20-007628.txt : 20200513
0001225208-20-007628.hdr.sgml : 20200513
20200513182849
ACCESSION NUMBER: 0001225208-20-007628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200511
FILED AS OF DATE: 20200513
DATE AS OF CHANGE: 20200513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Szyman Catherine M.
CENTRAL INDEX KEY: 0001438538
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 20874756
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES CORPORATION
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER NAME:
FORMER CONFORMED NAME: Szyman Catherine M
DATE OF NAME CHANGE: 20080625
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0306
4
2020-05-11
0001099800
Edwards Lifesciences Corp
EW
0001438538
Szyman Catherine M.
ONE EDWARDS WAY
IRVINE
CA
92614
1
CVP, Critical Care
Common Stock
2020-05-11
4
M
0
5950.0000
0
A
18317.8898
D
Common Stock
2020-05-11
4
F
0
548.0000
217.8400
D
17769.8898
D
Common Stock
2020-05-11
4
F
0
2951.0000
217.8400
D
14818.8898
D
Common Stock
2020-05-12
4
F
0
682.0000
225.0500
D
14136.8898
D
Common Stock
2020-05-13
4
S
0
750.0000
216.9300
D
13386.8898
D
Performance Rights
2020-05-11
4
M
0
5950.0000
0.0000
D
2020-05-11
Common Stock
5950.0000
0.0000
D
On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2020-05-13